

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 304 987 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **11.11.92** (51) Int. Cl.⁵: **A61K 31/19, A23L 1/29**

(21) Application number: **88201734.6**

(22) Date of filing: **15.08.88**

The file contains technical information submitted
after the application was filed and not included in
this specification

(54) Novel calcium supplements.

(30) Priority: **28.08.87 US 90813**

(43) Date of publication of application:
01.03.89 Bulletin 89/09

(45) Publication of the grant of the patent:
11.11.92 Bulletin 92/46

(54) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited:
EP-A- 0 297 679
FR-A- 2 601 249

**CHEMICAL ABSTRACTS, vol. 96, no. 5, 1st
February 1982, page 605, abstract no.
34574n, Columbus, Ohio, US**

**CALCIFIED TISSUE INTERNATIONAL, vol. 41,
no. 6, December 1987, pages 351-352,
Springer-Verlag, New York, Inc., US; K.T.
SMITH et al.: "Calcium absorption from a
new calcium delivery system (CCM)"**

(73) Proprietor: **Norwich Eaton Pharmaceuticals,
Inc.**
17 Eaton Avenue
Norwich New York 13815(US)

(72) Inventor: **Jacobs, Stephen Allen**
757 Story Drive
Fairfield, OH 45014(US)

(74) Representative: **Brooks, Maxim Courtney et al**
**Procter & Gamble European Technical Cen-
ter Temselaan 100**
B-1853 Strombeek-Bever(BE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention relates to a material and composition useful as a calcium supplement for humans and other animals. In particular, this invention relates to specific calcium citrate malate materials and dosage forms containing such materials.

Calcium is the fifth most abundant element in the human body. It plays an important role in many physiological processes, including nerve and muscle functions. Not surprisingly, nutritional and metabolic deficiencies of calcium can have broad-ranging adverse effects. Since about 90% of the body's calcium is found in bone tissues, many of these adverse effects are manifested through deficiencies in the structure, function and integrity of the skeletal system.

The most common metabolic bone disorder is osteoporosis. Osteoporosis can be generally defined as the reduction in the quantity of bone, or the atrophy of skeletal tissue. In general, there are two types of osteoporosis: primary and secondary. "Secondary osteoporosis" is the result of an identifiable disease process or agent. However, approximately 90% of all osteoporosis cases is idiopathic "primary osteoporosis". Such primary osteoporosis includes postmenopausal osteoporosis, age-associated osteoporosis (affecting a majority of individuals over the age of 70 to 80), and idiopathic osteoporosis affecting middle-aged and younger men and women.

For some osteoporotic individuals the loss of bone tissue is sufficiently great so as to cause mechanical failure of the bone structure. Bone fractures often occur, for example, in the wrist and spine of women suffering from postmenopausal osteoporosis. Kyphosis (abnormally increased curvature of the thoracic spine) may also result.

The mechanism of bone loss in osteoporotics is believed to involve an imbalance in the process of "bone remodeling". Bone remodeling occurs throughout life, renewing the skeleton and maintaining the strength of bone. This remodeling occurs in a series of discrete pockets of activity in the bone, called "osteoclasts" and "osteoblasts". Osteoclasts (bone dissolving or resorbing cells) are responsible for the resorption of a portion of bone within the bone matrix, during the resorption process. After resorption, the osteoclasts are followed by the appearance of osteoblasts (bone forming cells), which then refill the resorbed portion with new bone.

In a healthy adult, the rate at which the osteoclasts and osteoblasts are formed maintains a balance of bone resorption and bone formation. However, in osteoporotics an imbalance in this remodeling process develops, resulting in loss of bone at a rate faster than the accretion of bone. This imbalance is much more severe, and occurs at a younger age, in osteoporotics as compared to healthy adults.

Many compositions and methods are described in the medical literature for the "treatment" of osteoporosis. Many of these compositions and methods attempt to either slow the loss of bone or to produce a net gain in bone mass. See, for example, R. C. Haynes, Jr. et al., "Agents affecting Calcification", *The Pharmacological Basis of Therapeutics*, 7th Edition (A. G. Gilman, L. S. Goodman et al., Editors, 1985); and G. D. Whedon et al., "An Analysis of Current Concepts and Research Interest in Osteoporosis", *Current Advances in Skeletogenesis* (A. Ornoy et al., Editors, 1985). Estrogen is often used to affect the metabolism of calcium. Treatments using fluoride have also been described. However, the utility of such agents may be limited, due to possible adverse side effects. See W. A. Peck, et al., *Physician's Resource Manual on Osteoporosis* (1987), published by the National Osteoporosis Foundation.

Nutritional therapies for osteoporosis have also been proposed. Many calcium-containing compounds and compositions have been described for use as nutritional supplements. Many commercial preparations are also available, typically containing calcium carbonate. Calcium chloride, calcium gluceptate, calcium gluconate, calcium lactate, calcium phosphate, calcium citrate, and other calcium salts have also been described for use in calcium supplements. The use of calcium citrate, for example, is described in French Patent 2,219,778, Monteau, published September 27, 1974; and World Patent Publications 86/04814 and 86/04815, Pak et al., both published August 28, 1986. Food supplements containing calcium citrate malate are described in Japanese Patent Document 56/97, 248, Kawai, published August 5, 1981.

The utility of these known supplements varies. Unlike agents (such as estrogen) which affect the metabolism of bone, calcium nutritional supplements have been thought to merely provide a source for calcium (which may or may not be properly absorbed and metabolized). Indeed, the literature is bereft of any credible clinical data supporting the utility of any of these calcium supplements to actually treat osteoporosis (to actually build bone). See, for example, B. Riis et al., "Does Calcium Supplementation Prevent Postmenopausal Bone Loss?", 316 *New England J. of Medicine* 173-177 (1987); L. Nilas et al., "Calcium Supplementation and Postmenopausal Bone Loss", 289 *British Medical Journal* 1103-1106 (1984); and H. Spencer et al., "NIH Consensus Conference: Osteoporosis", 116 *Journal of Nutrition* 316-319 (1986).

It has now been discovered, however, that certain calcium citrate malate materials are highly efficacious

calcium supplements, providing increased absorption and bioavailability compared to calcium supplements known in the art. In particular, as compared to calcium supplements known in the art, these calcium citrate malate materials afford greater efficacy in the treatment of osteoporosis and related disorders.

5 SUMMARY OF THE INVENTION

The present invention provides a calcium citrate malate complex or mixture having a molar composition of calcium:citrate:malate of 6:2:3. The calcium citrate malate is preferably administered in an oral dosage form, containing pharmaceutically-acceptable carriers and excipients.

10 DESCRIPTION OF THE INVENTION

The present invention encompasses a calcium citrate malate, and dose forms for the administration of the calcium citrate malate to a human or other animal subject. Specific compounds and compositions to be used in the invention must, accordingly, be pharmaceutically-acceptable. As used herein, such a "pharmaceutically-acceptable" component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. Further, as used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed.

25 Calcium Citrate Malate and Compositions:

This invention provides a mixture of calcium salts, herein "calcium citrate malate", comprising calcium salts of citric acid and malic acid, having a molar ratio of calcium:citrate:malate of 6:2:3. The calcium citrate malate may consist of a mixture of calcium citrate and calcium malate, a complex of calcium containing citrate and malate ligands, a mixture of a calcium salt with citric acid and malic acid, or combinations thereof. (Mixtures of calcium salt and citric and malic acids may be used to form calcium citrate malate in situ, in a liquid dose form, or in the acid environment of the stomach of the subject to whom the mixture is administered.)

The calcium citrate malate materials according to this invention may be provided in solid or liquid dosage forms (herein "calcium supplements"). Calcium citrate malate for use in solid forms may be made, for example, by first dissolving citric acid and malic acid, in the desired molar ratio, in water. Calcium carbonate may then be added to the solution, in such amount that the ratio of moles calcium to moles citrate and moles malate is as desired. Carbon dioxide will be evolved. The solution may then be dried (as by freeze drying or oven drying) to obtain the calcium citrate malate. The calcium citrate malate made in such commercial processes may, of course, vary from a precise 6:2:3 molar composition. Such commercial calcium citrate malate may contain, therefore, other anions such as (for example) carbonate, hydroxide, and mixtures thereof.

Various oral dosage forms of calcium citrate malate may be used in the present invention. Such dosage forms comprise a safe and effective amount of a calcium citrate malate of this invention and a pharmaceutically-acceptable carrier. Preferably the pharmaceutically-acceptable carrier is present at a level of from 0.1% to 99%, preferably from 0.1% to 75%, by weight of the composition. Unit dosage forms (i.e., compositions containing an amount of calcium citrate malate suitable for administration in one single dose, according to sound medical practice) preferably contain from 425 mg (milligrams) to 4300 mg of calcium citrate malate, corresponding to from 100 mg to 1000 mg of calcium (on an elemental basis). Preferably, the unit dosage forms of this invention contain from 425 mg to 2100 mg, more preferably from 850 mg to 1300 mg of calcium citrate malate.

Solid dosage forms include tablets, capsules, granules and bulk powders. Aside from the calcium citrate malate, tablets may contain, as carriers (for example), suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, melting agents, and mixtures thereof. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such oral dosage forms may contain, as carriers (for example), suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents, flavoring

agents, and mixtures thereof.

Specific examples of pharmaceutically-acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in U. S. Patent 3,903,297, Robert, issued September 2, 1975. Techniques and compositions for making dosage forms useful in the methods of this invention are described in the following references 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms 2d Edition. (1976).

Methods of Use:

Calcium citrate malate materials according to The present invention are used in methods for the administration of a calcium supplement to a human or other animal subject in need thereof. Preferably, from 750 mg to 8600 mg of calcium citrate malate are administered to said subject, per day, corresponding to from 175 mg to 2000 mg of calcium (on an elemental basis). More preferably, from 1000 mg to 6400 mg, more preferably from 2100 mg to 4300 mg of calcium citrate malate are administered, per day. "Administering" refers to any method which, in sound medical practice, delivers the calcium citrate malate used in this invention to the subject to be treated in such a manner so as to be effective in the building of bone. Preferably, the calcium citrate malate is administered orally.

The specific period of time for which the calcium citrate malate is to be administered may depend upon a variety of factors. Such factors include, for example, the amount of calcium citrate malate employed, the specific condition to be treated, the age and sex of the subject, the nutritional habits of the individual, and the general health of the individual (including the presence of other disorders). The calcium citrate malate materials of this invention may be employed in the treatment or prevention of any of a variety of disorders. Thus, preferably, the calcium citrate malate materials of this invention are employed on a "subject" that is "in need" of treatment or prevention of such disorders, according to sound medical practice. The calcium citrate malate and the calcium supplements of this invention may be used to replace or supplement other dietary sources of calcium for humans or other animals. The calcium citrate malate and supplements may be used to assure adequate intake of calcium for metabolic needs, or to prevent or treat certain disorders.

Calcium citrate malate materials of this invention are used in the treatment of osteoporosis. calcium citrate malate can be administered alone, or in combination with other therapeutic agents. In particular, calcium citrate malate materials of the invention can be administered as part of an "ADFR" regimen. Such a regimen, in general, comprises administration to the subject of a bone-cell activation agent (such as an inorganic phosphate); followed by administration of an osteoclast depressant, to inhibit bone resorption (such as a diphosphonate); followed by a "free" period during which osteoblast bone formation occurs. The entire cycle is preferably repeated. Such regimens, among those useful herein, are described in Belgian Patent Publication 902,307, Anderson et al., "Treatment of Osteoporosis", published October 29, 1985 and Belgian Patent Publication 902,308, Flora, "Treatment of Osteoporosis", published October 29, 1985. Preferably, in such regimens calcium citrate malate is administered during the free period. Kits to facilitate ADFR regimens are described in European Patent Specification 162,510, Uchtman, "Kit for Use in the Treatment of Osteoporosis", published November 27, 1985.

As an alternative, calcium citrate malate materials of this invention can be administered as part of a regimen comprising intermittent dosing of certain polyphosphonate compounds. Such regimens comprise administration of the polyphosphonate followed by a "rest period". Such regimens, among those useful herein, are described in European Patent Specification 210,728, Flora et al., "Regimen for Treating Osteoporosis", published February 4, 1987. Preferably, calcium citrate malate is administered during the rest period.

The following non-limiting examples illustrate the compositions, processes and uses of the present invention.

EXAMPLE 1

A composition is prepared containing calcium citrate malate having a molar calcium:citrate:malate composition of about 6:2:3. The calcium citrate malate is made by first dissolving approximately 384.2 g of citric acid and approximately 402.3 g of malic acid in approximately 2 liters of water. This citrate/malate solution is then heated to approximately 55 °C (131 °F), with stirring. Separately, approximately 600.6 g of calcium carbonate is added to approximately 1.2 liters of water, forming a slurry, with stirring.

The citrate/malate solution is then removed from its heat source, and the calcium carbonate slurry is added slowly, with stirring. The rate of addition is controlled, to contain the reaction as carbon dioxide is

released. An additional quantity of water, approximately 0.4 liters, is finally added. The reaction mixture is then stirred for approximately 1 to 1.5 hours. The reaction is essentially complete as the pH of the solution equilibrates to approximately 4.3.

A precipitate of calcium citrate malate is thus formed. The excess reaction liquid is filtered off. The calcium citrate malate is dried, for approximately 12 hours, at approximately 105°C (221°F), reducing the moisture level to less than about 1%. The dried product is then milled to approximately 2-4 mm (10-20 mesh) size, for a swallowable tablet formulation.

The swallowable tablet dosage form is then made, comprising:

Component	% (by weight)
calcium citrate malate*	99.73
magnesium stearate	0.27

*: having a molar calcium:citrate:malate composition of approximately 6:2:3, made as described above in this Example.

The tablet formulation is made by thoroughly admixing the powders, and tableting using a standard tablet press, to form tablets weighing approximately 1104 mg. The tablets are then coated, using a pan coater. The coating solution contains approximately 11% hydroxypropylmethyl cellulose, approximately 2% polyethylene glycol, approximately 3.5% colorant, and the balance of water.

The composition is administered to an elderly human male subject suffering from osteoporosis. The mass of the subject's thoracic vertebrae is determined by dual-energy photon absorptiometry. The human subject is then administered 4 of the tablets, comprised as above, each day for three months. The mass of the subject's vertebrae is then remeasured, indicating an increase in bone mass.

EXAMPLE II

A human male subject, suffering from secondary osteoporosis as a result of a partial gastrectomy, is treated by a method of this invention. Specifically, a chewable tablet composition is administered to the subject, comprised as set forth below.

Component	% (by weight)
calcium citrate malate*	46.94
mannitol	46.69
magnesium stearate	0.68
flavorant	5.69

* having a molar calcium:citrate:malate composition of approximately 6:2:3, made in a manner analogous to that described in Example I, above.

The tablets are made by thoroughly admixing the powders, and tableting on a standard tablet press, forming tablets weighing approximately 2356 mg. Each tablet contains approximately 250 mg of calcium (on an elemental basis). The composition comprised as above, when administered to a pregnant female human, is effective in providing a sufficient quantity of bioavailable calcium.

Claims

1. Calcium citrate malate, having a molar ratio of calcium:citrate:malate of 6:2:3.
2. A complex of calcium containing citrate and malate ligands, according to Claim 1.
3. A calcium supplement comprising a safe and effective amount of a calcium citrate malate of Claim 1, and a pharmaceutically-acceptable carrier.
4. A calcium supplement, according to Claim 3, in unit dosage form comprising from 425 milligrams to

2100 milligrams of said calcium citrate malate.

5. A calcium supplement, according to claim 3, in solid dosage form wherein said pharmaceutically-acceptable carrier is present at a level of from 0.1% to 75%, by weight.

Patentansprüche

1. Calciumcitratmalat, welches ein Molverhältnis von Calcium:Citrat:Malat von 6:2:3 aufweist.
2. Calciumkomplex, welcher Citrat- und Malatliganden gemäß Anspruch 1 enthält.
3. Calcium-Diätergänzungsmittel, welches eine sichere und wirksame Menge eines Calciumcitratmalates nach Anspruch 1 und einen pharmazeutisch annehmbaren Träger enthält.
4. Calcium-Diätergänzungsmittel nach Anspruch 3, in Einheitsdosierungsform, welche 425 mg bis 2100 mg des Calciumcitratmalates enthält.
5. Calcium-Diätergänzungsmittel nach Anspruch 3, in fester Dosierungsform, wobei der pharmazeutisch annehmbare Träger in einer Menge von 0,1 Gew.-% bis 75 Gew.-% vorliegt.

Revendications

1. Citrate-malate de calcium, ayant un rapport molaire calcium/citrate/malate de 6:2:3.
2. Complexe de calcium contenant des ligands citrate et malate, selon la revendication 1.
3. Supplément calcique comprenant une quantité sans danger et efficace d'un citrate-malate de calcium selon la revendication 1 et un véhicule pharmaceutiquement acceptable.
4. Supplément calcique selon la revendication 3, sous une forme galénique unitaire comprenant de 425 mg à 2100 mg dudit citrate-malate de calcium.
5. Supplément calcique selon la revendication 3, sous une forme galénique unitaire, dans lequel ledit véhicule pharmaceutiquement acceptable est présent en une proportion de 0,1% à 75% en poids.

REGISTER ENTRY FOR EP0304987

European Application No EP88201734.6 filing date 15.08.1988

Priority claimed:

28.08.1987 in United States of America - doc: 90813

Designated States BE CH DE FR GB IT LI LU NL SE AT

Title NOVEL CALCIUM SUPPLEMENTS.

Applicant/Proprietor

NORWICH EATON PHARMACEUTICALS, INC., 17 Eaton Avenue, Norwich New York
13815, United States of America [ADP No. 50110196001]

Inventor

STEPHEN ALLEN JACOBS, 757 Story Drive, Fairfield, OH 45014, United States
of America [ADP No. 56367238001]

Classified to

A23L A61K

Address for Service

PROCTER & GAMBLE, P.O. Box Forest Hall No. 2, NEWCASTLE UPON TYNE, United
Kingdom [ADP No. 00022533001]

EPO Representative

HUBERT ERNST, PROCTER & GAMBLE EUROPEAN TECHNICAL CENTER N.V. Temselaan
100, B-1820 Strombeek-Bever, Belgium [ADP No. 50261700001]

Publication No EP0304987 dated 01.03.1989

Publication in English

Examination requested 11.08.1990

Patent Granted with effect from 11.11.1992 (Section 25(1)) with title NOVEL
CALCIUM SUPPLEMENTS.

17.04.1989 Notification from EPO of change of EPO Representative details from
HUBERT ERNST, PROCTER & GAMBLE EUROPEAN TECHNICAL CENTER N.V.
Temselaan 100, B-1820 Strombeek-Bever, Belgium

[ADP No. 50261700001]

to

MAXIM COURTNEY BROOKS, Procter & Gamble European Technical Center
Temselaan 100, B-1820 Strombeek-Bever, Belgium

[ADP No. 50716257001]

Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

23.01.1990 EPO: Search report published on 21.02.1990

Entry Type 25.11 Staff ID. Auth ID. EPT

12.10.1992 Notification from EPO of change of EPO Representative details from
MAXIM COURTNEY BROOKS, Procter & Gamble European Technical Center
Temselaan 100, B-1820 Strombeek-Bever, Belgium

[ADP No. 50716257001]

to

MAXIM COURTNEY BROOKS, Procter & Gamble European Technical Center
Temselaan 100, B-1853 Strombeek-Bever, Belgium

[ADP No. 50716257001]

Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

20.10.1992 PROCTER & GAMBLE, P.O. Box Forest Hall No. 2, NEWCASTLE UPON TYNE,
United Kingdom
registered as address for service

[ADP No. 00022533001]

Entry Type 8.11 Staff ID. DC1 Auth ID. AA

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

25/03/96 10:03:22
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER EP0304987

PROPRIETOR(S)

Norwich Eaton Pharmaceuticals, Inc., 17 Eaton Avenue, Norwich New
York 13815, United States of America

DATE FILED 15.08.1988

DATE GRANTED 11.11.1992

DATE NEXT RENEWAL DUE 15.08.1996

DATE NOT IN FORCE

DATE OF LAST RENEWAL 04.08.1995

YEAR OF LAST RENEWAL 08

STATUS PATENT IN FORCE

**** END OF REPORT ****